130 related articles for article (PubMed ID: 33852456)
1. Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry: Concordance With the ILROG Guidelines.
Tseng YD; Pankuch M; Mohindra P; McGee L; Rossi C; Flampouri S; Hajj C; Molitoris JK; Chang JH; Tsai H; Stevens C; Rosen L; Vargas C; Hartsell W
Am J Clin Oncol; 2021 Jun; 44(6):269-274. PubMed ID: 33852456
[TBL] [Abstract][Full Text] [Related]
2. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines.
Dabaja BS; Hoppe BS; Plastaras JP; Newhauser W; Rosolova K; Flampouri S; Mohan R; Mikhaeel NG; Kirova Y; Specht L; Yahalom J
Blood; 2018 Oct; 132(16):1635-1646. PubMed ID: 30108066
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy.
Loap P; Orlandi E; De Marzi L; Vitolo V; Barcellini A; Iannalfi A; Dendale R; Kirova Y; Mirandola A
Acta Oncol; 2022 Aug; 61(8):979-986. PubMed ID: 35668710
[TBL] [Abstract][Full Text] [Related]
4. Comparative photon and proton dosimetry for patients with mediastinal lymphoma in the era of Monte Carlo treatment planning and variable relative biological effectiveness.
Tseng YD; Maes SM; Kicska G; Sponsellor P; Traneus E; Wong T; Stewart RD; Saini J
Radiat Oncol; 2019 Dec; 14(1):243. PubMed ID: 31888769
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group.
Maraldo MV; Dabaja BS; Filippi AR; Illidge T; Tsang R; Ricardi U; Petersen PM; Schut DA; Garcia J; Headley J; Parent A; Guibord B; Ragona R; Specht L
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):144-52. PubMed ID: 25670544
[TBL] [Abstract][Full Text] [Related]
6. Protontherapy versus best photon for mediastinal Hodgkin lymphoma: Dosimetry comparison and treatment using ILROG guidelines.
Abbassi LM; Goudjil F; Arsène-Henry A; Dendale R; Kirova YM
Cancer Radiother; 2019 Dec; 23(8):922-925. PubMed ID: 31257097
[TBL] [Abstract][Full Text] [Related]
7. Consolidative active scanning proton therapy for mediastinal lymphoma: selection criteria, treatment implementation and clinical feasibility.
Dionisi F; Scartoni D; Rombi B; Vennarini S; Righetto R; Farace P; Lorentini S; Schwarz M; Di Murro L; Demofonti C; D'Angelillo RM; Petrongari MG; Sanguineti G; Amichetti M
Strahlenther Onkol; 2022 Jun; 198(6):558-565. PubMed ID: 35394144
[TBL] [Abstract][Full Text] [Related]
8. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
[TBL] [Abstract][Full Text] [Related]
9. Comparative treatment planning study for mediastinal Hodgkin's lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy.
Edvardsson A; Kügele M; Alkner S; Enmark M; Nilsson J; Kristensen I; Kjellén E; Engelholm S; Ceberg S
Acta Oncol; 2019 Jan; 58(1):95-104. PubMed ID: 30280626
[TBL] [Abstract][Full Text] [Related]
10. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.
Hoppe BS; Flampouri S; Zaiden R; Slayton W; Sandler E; Ozdemir S; Dang NH; Lynch JW; Li Z; Morris CG; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1053-1059. PubMed ID: 24928256
[TBL] [Abstract][Full Text] [Related]
11. Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison.
König L; Bougatf N; Hörner-Rieber J; Chaudhri N; Mielke T; Klüter S; Haefner MF; Rieken S; Haberer T; Debus J; Herfarth K
Strahlenther Onkol; 2019 Jul; 195(7):677-687. PubMed ID: 30972453
[TBL] [Abstract][Full Text] [Related]
12. Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin's disease.
Lautenschlaeger S; Iancu G; Flatten V; Baumann K; Thiemer M; Dumke C; Zink K; Hauswald H; Vordermark D; Mauz-Körholz C; Engenhart-Cabillic R; Eberle F
Radiat Oncol; 2019 Sep; 14(1):157. PubMed ID: 31477141
[TBL] [Abstract][Full Text] [Related]
13. Clinical implementation of intensity modulated proton therapy for thoracic malignancies.
Chang JY; Li H; Zhu XR; Liao Z; Zhao L; Liu A; Li Y; Sahoo N; Poenisch F; Gomez DR; Wu R; Gillin M; Zhang X
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):809-18. PubMed ID: 25260491
[TBL] [Abstract][Full Text] [Related]
14. Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment.
Zeng C; Plastaras JP; James P; Tochner ZA; Hill-Kayser CE; Hahn SM; Both S
Acta Oncol; 2016; 55(9-10):1132-1138. PubMed ID: 27332881
[TBL] [Abstract][Full Text] [Related]
15. Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration.
Tseng YD; Hoppe BS; Dedeckova K; Patel CG; Hill-Kayser CE; Miller DM; Maity A; Mendenhall NP; Mailhot Vega RB; Yock TI; Baliga S; Hess CB; Winkfield KM; Mohindra P; Rosen LR; Tsai H; Chang J; Hartsell WF; Plastaras JP
Int J Radiat Oncol Biol Phys; 2021 Jan; 109(1):220-230. PubMed ID: 32866566
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
Lu NN; Li YX; Wu RY; Zhang XM; Wang WH; Jin J; Song YW; Fang H; Ren H; Wang SL; Liu YP; Liu XF; Chen B; Dai JR; Yu ZH
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):210-6. PubMed ID: 22436783
[TBL] [Abstract][Full Text] [Related]
17. Clinical and technical considerations for mediastinal Hodgkin lymphoma protontherapy based on a single-center early experience.
Loap P; Goudjil F; Dendale R; Kirova Y
Cancer Radiother; 2021 Dec; 25(8):779-785. PubMed ID: 34275748
[TBL] [Abstract][Full Text] [Related]
18. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.
Pinnix CC; Smith GL; Milgrom S; Osborne EM; Reddy JP; Akhtari M; Reed V; Arzu I; Allen PK; Wogan CF; Fanale MA; Oki Y; Turturro F; Romaguera J; Fayad L; Fowler N; Westin J; Nastoupil L; Hagemeister FB; Rodriguez MA; Ahmed S; Nieto Y; Dabaja B
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):175-82. PubMed ID: 25863764
[TBL] [Abstract][Full Text] [Related]
19. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk.
Filippi AR; Ragona R; Piva C; Scafa D; Fiandra C; Fusella M; Giglioli FR; Lohr F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):161-8. PubMed ID: 25863763
[TBL] [Abstract][Full Text] [Related]
20. Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy.
Horn S; Fournier-Bidoz N; Pernin V; Peurien D; Vaillant M; Dendale R; Fourquet A; Kirova YM
Cancer Radiother; 2016 Apr; 20(2):98-103. PubMed ID: 26992750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
